Liver Diseases
Also known as: Hepatic diseases, Hepatic mass, Liver, Hepatic, Biliary
Methodology & AI Transparency ⓘ
Liver Diseases Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Your liver is the largest organ inside your body.
- 2 Real-world patient consensus: Clinical coding for Liver Diseases uses ICD-10 R16.0 across Liver & Hepatology specialty care.
- 3 Typical cash cost range: Clinicians assessing Liver Diseases focus on viral/autoimmune hepatocyte injury [Liver Diseases R16.0] and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Liver Diseases: Fasting Lipase & in Liver Diseases (R16.0: Triglycerides) (Normal enzymatic baseline (R16.0)) and ALT, AST, Alkaline in Liver Diseases (R16.0: Phosphatase & GGT).
Ask our AI Specialists anything about Liver Diseases
What Is Liver Diseases?
Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. There are many kinds of liver diseases: Diseases caused by viruses, such as hepatitis A , hepatitis B , and hepatitis C . Diseases caused by drugs, poisons, or too much alcohol. Examples include steatotic liver disease and cirrhosis . Liver cancer . Inherited diseases, such as hemochromatosis and Wilson disease . Symptoms of liver disease can vary, but they often include swelling of the abdomen and legs, bruising easily, changes in the color of your stool and urine, and jaundice , or yellowing of the skin and eyes. Sometimes there are no symptoms.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Liver Diseases (ICD-10 R16.0) is driven by viral/autoimmune hepatocyte injury [Liver Diseases R16.0]; Cross-referenced with NIH MeSH (Liver Diseases), specialists in Liver, Gallbladder & Pancreatic Health monitor ALT, AST, Alkaline in Liver Diseases (R16.0: Phosphatase & GGT) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Diseases caused by viruses, such as hepatitis A , hepatitis B , and hepatitis C
- • Diseases caused by drugs, poisons, or too much alcohol. Examples include steatotic liver disease and cirrhosis
- • Presentation of Liver Diseases (R16.0): epigastric pain, steatorrhea [Liver Diseases R16.0]
- • Secondary Liver Diseases clinical sign: asymptomatic elevation of in Liver Diseases (R16.0: liver transaminases)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Liver Diseases Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R16.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Liver, Gallbladder & Pancreatic Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Lipase & in Liver Diseases (R16.0: Triglycerides) | Normal enzymatic baseline (R16.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ALT, AST, Alkaline in Liver Diseases (R16.0: Phosphatase & GGT) | ALT < 25 U/L (men) / < 19 U/L (women) (R16.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: FIB-4 Hepatic Fibrosis in Liver Diseases (R16.0: Index) | < 1.30 (R16.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Liver Diseases
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Hevert Detox Liver (Milk Thistle, Chelidonium Majus Root, and Taraxacum Officinale) Hevert Detox Liver • RxCUI RXN-B545320033 | Over-the-Counter Clinical Monograph | 93% | $0.0065 | $ 8.97 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Liver Diseases)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic: What a 2,178-Participant Study Found This study evaluated the efficacy of GLP-1RAs in patients with NAFLD and NASH. Primary care diabetes • 2024-06-15 • Meta-Analysis | N = 2,178 | 99/100 | PMID 38555202 ↗ |
| New Insights on Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic: What a 1,778-Participant Study Found This study did not demonstrate the efficacy of CVC for treating liver fibrosis assessed by histology in adults with NASH; however, CVC was safe and well tolerated in patients with NASH and liver fibrosis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2024-01-15 • Phase III Randomized Trial | N = 1,778 | 96/100 | PMID 37061109 ↗ |
| Check Your Medicine Cabinet: Early Alert: Transcatheter Mitral Valve Delivery System Issue from Edwards Lifesciences Potential balloon burst during inflation can lead to embolism or the need for surgery. FDA MedWatch Safety Alerts • 2026-10-15 • FDA Safety Alert | Multi-cohort | 95/100 | PMID FDA_MEDWATCH-1936956490 ↗ |
| New Insights on Eptinezumab on self-reported work productivity in adults with migraine and prior: What a 890-Participant Study Found In adults with migraine and prior preventive treatment failure, eptinezumab 100 mg and 300 mg IV every 12 weeks improved absenteeism, presenteeism, work productivity loss, and activity impairment more than placebo. The journal of headache and pain • 2022-12-02 • Phase III Randomized Trial | N = 890 | 93/100 | PMID 36460983 ↗ |
| New Insights on Resmetirom for nonalcoholic fatty liver disease: a randomized, gold-standard: What a 325-Participant Study Found These findings demonstrate resmetirom was safe and well tolerated in adults with presumed NASH, supporting a role for further clinical development. Nature medicine • 2023-11-15 • Phase III Randomized Trial | N = 325 | 93/100 | PMID 37845512 ↗ |
Liver Diseases Patient Community & “People Like Me” Threads
Filter Liver Diseases community threads and patient logs by age, biological sex, dosage, and treatment duration.